ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
120.767,19
-1,73%
S&P 500
5.346,99
-0,11%
US Dollar vs BRL
5,3461
1,66%
Bitcoin
69.361,22
-1,98%
Brent Oil
79,395
-0,61%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. AMEX
  6. Biosante Pharmaceuticals (BPA)

  7. Biosante Pharmaceuticals (BPA) Notícias

BPA

Biosante Pharma (BPA)

Biosante Pharmaceuticals
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:AMEX:BPA
DataHoraFonteTítuloCódigoCompanhia
31/10/200719:21Edgar (US Regulatory)Biosante Pharmaceuticals Inc - Amended Securities Registration (section 12(b)) (8-A12B/A)AMEX:BPABiosante Pharmaceuticals
24/10/200713:23Edgar (US Regulatory)Biosante Pharmaceuticals Inc - Current report filing (8-K)AMEX:BPABiosante Pharmaceuticals
24/10/200713:23Edgar (US Regulatory)Biosante Pharmaceuticals Inc - Current report filingAMEX:BPABiosante Pharmaceuticals
24/09/200714:57PR Newswire (US)WallSt.net Announces Upcoming Interview with CEO of BioSante PharmaceuticalsAMEX:BPABiosante Pharmaceuticals
14/08/200717:15Business WireBioSante Pharmaceuticals Reports Second Quarter 2007 Financial ResultsAMEX:BPABiosante Pharmaceuticals
08/08/200709:00Business WireBioSante Pharmaceuticals to Present at Upcoming ConferencesAMEX:BPABiosante Pharmaceuticals
25/07/200709:00Business WireBioSante Pharmaceuticals Announces Positive Results for its CaP Technology for Use in Aesthetic MedicineAMEX:BPABiosante Pharmaceuticals
11/07/200709:00Business WireBioSante Pharmaceuticals Announces New Findings for Potential Bird Flu VaccineAMEX:BPABiosante Pharmaceuticals
10/07/200708:00PR Newswire (US)WallSt.net (www.wallst.net ) Updates the Investment Community Through All-New Interviews with BPA, PPCO and NVAXAMEX:BPABiosante Pharmaceuticals
28/06/200708:00Business WireBioSante Pharmaceuticals, Inc. Joins Russell Microcap IndexAMEX:BPABiosante Pharmaceuticals
19/06/200709:00Business WireBioSante Pharmaceuticals Announces Oral Contraceptive Phase II Study InitiationAMEX:BPABiosante Pharmaceuticals
14/06/200709:00Business WireBioSante Pharmaceuticals Completes $18.3 Million Private Placement of Common StockAMEX:BPABiosante Pharmaceuticals
13/06/200709:45PR Newswire (US)Bradley Pharmaceuticals Announces Launch of Elestrin(TM)AMEX:BPABiosante Pharmaceuticals
25/05/200710:26Business WireBioSante Pharmaceuticals Announces $16.5 Million Private Placement of Common StockAMEX:BPABiosante Pharmaceuticals
07/05/200709:00Business WireBioSante Pharmaceuticals Signs Oral Contraceptive License with Pantarhei BioscienceAMEX:BPABiosante Pharmaceuticals
04/05/200709:45PR Newswire (US)Bradley Pharmaceuticals to Preview New Products at ACOG MeetingAMEX:BPABiosante Pharmaceuticals
01/05/200718:00Business WireBioSante Pharmaceuticals Reports First Quarter 2007 Financial ResultsAMEX:BPABiosante Pharmaceuticals
11/04/200709:45PR Newswire (US)Bradley Pharmaceuticals' Elestrin(TM) Receives New Patent to 2022AMEX:BPABiosante Pharmaceuticals
10/04/200709:00Business WireBioSante Pharmaceuticals Announces Issuance of New Patent Covering Elestrin(TM) and LibiGel(R)AMEX:BPABiosante Pharmaceuticals
02/04/200715:09PR Newswire (US)Dawson James Securities Reiterates Strong Buy Recommendation on Antares Pharma (Amex: AIS) with $4.00 Price TargetAMEX:BPABiosante Pharmaceuticals
26/03/200708:30Business WireBioSante Pharmaceuticals Receives Milestone Payment from Bradley PharmaceuticalsAMEX:BPABiosante Pharmaceuticals
08/03/200718:34Business WireBioSante Pharmaceuticals Reports Net Profit of $2.8 million for 2006 And Investor Conference CallAMEX:BPABiosante Pharmaceuticals
30/01/200711:00Business WireBioSante Pharmaceuticals Announces Positive Bird Flu Results Using Proprietary Vaccine Adjuvant in Pre-Clinical StudyAMEX:BPABiosante Pharmaceuticals
16/01/200712:00Business WireStephen M. Simes, President and CEO of BioSante Pharmaceuticals, Inc., Talks to The Wall Street TranscriptAMEX:BPABiosante Pharmaceuticals
19/12/200610:45PR Newswire (US)Bradley Pharmaceuticals Announces FDA Approval of Elestrin(TM) (estradiol gel 0.06%)AMEX:BPABiosante Pharmaceuticals
04/12/200611:00Business WireBioSante Pharmaceuticals to Present at Upcoming Biotech/Specialty Pharma and Investor ConferencesAMEX:BPABiosante Pharmaceuticals
14/11/200611:00Business WireBioSante Pharmaceuticals Reports Third Quarter 2006 Financial Results And Reviews Bio-E-Gel(R) Marketing AgreementAMEX:BPABiosante Pharmaceuticals
08/11/200610:45Business WireBioSante Pharmaceuticals Signs Bio-E-Gel(R) Marketing Agreement With Bradley Pharmaceuticals, Inc.AMEX:BPABiosante Pharmaceuticals
08/11/200610:45PR Newswire (US)Bradley Pharmaceuticals Enters Into Agreement With BioSante Pharmaceuticals for Estradiol Transdermal GelAMEX:BPABiosante Pharmaceuticals
03/11/200610:00Business WireBioSante Pharmaceuticals to Present at Rodman & Renshaw 8th Annual Healthcare ConferenceAMEX:BPABiosante Pharmaceuticals
 Apresentando as notícias mais relevantes sobre:AMEX:BPA

Seu Histórico Recente

NYSE
MDVA
Modiv
USOTC
PSBKF
Postal Savings Bank of C... (PK)
BIT
SMOT
Ucits Etfs
BIT
UC1H1U
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados